Passage Bio(PASG.US)

Last Updated 19:00:00 ET
longbridge loading

Passage Bio | 10-Q: FY2026 Q1 Revenue: USD 0

Earnings Watch·
US
PASG
-0.77%
Earnings Watch·
US
PASG
-0.77%

This Mohawk Industries Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Tuesday

benzinga_article·
US
PASG
-0.77%
US
MHK
+1.90%
US
XLB
+0.60%
benzinga_article·
US
PASG
-0.77%
US
MHK
+1.90%
US
XLB
+0.60%

Buy Rating Reaffirmed on Encouraging upliFT-D Biomarker Data and Solid Cash Runway Supporting Expanded FTD-GRN Trial

Tip Ranks·
US
PASG
-0.77%
US
XBI
+0.81%
US
BBH
+0.64%
Tip Ranks·
US
PASG
-0.77%
US
XBI
+0.81%
US
BBH
+0.64%

Pre-market hot trades in US stocks: UnitedHealth up 5.73% pre-market; Passage Bio up 5.60% pre-market

Price Alert·
US
UNH
-0.21%
US
PASG
-0.77%
Price Alert·
US
UNH
-0.21%
US
PASG
-0.77%

12 Health Care Stocks Moving In Monday's Intraday Session

benzinga_article·
US
TOVX
-1.13%
US
PASG
-0.77%
US
CMND
-2.38%
benzinga_article·
US
TOVX
-1.13%
US
PASG
-0.77%
US
CMND
-2.38%

Passage Bio shares are trading lower after the company announced the FDA did not support a single-arm trial design for its indication in the Type C meeting and instead indicated that a randomized controlled trial would be required for registrational purposes. Also, the company announced it initiated a review of strategic alternatives to maximize shareholder value.

benzinga_article·
US
PASG
-0.77%
US
BIB
+1.41%
US
IBBQ
+0.82%
benzinga_article·
US
PASG
-0.77%
US
BIB
+1.41%
US
IBBQ
+0.82%

Passage Bio reports biomarker improvements, FDA says randomized registrational trial required

TradingView·
US
PASG
-0.77%
US
BIB
+1.41%
US
LABU
+2.48%
TradingView·
US
PASG
-0.77%
US
BIB
+1.41%
US
LABU
+2.48%
© 2026 Longbridge｜Disclaimer